Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from TScan Therapeutics ( (TCRX) ) is now available.
TScan Therapeutics has entered a new loan agreement with Silicon Valley Bank, securing up to $52.5 million to refinance existing debt and fund corporate purposes. This non-dilutive financing extends the loan maturity to 2029, enhances TScan’s financial flexibility, and supports its ongoing development efforts in advancing cancer therapies, potentially benefiting patients and investors.
More about TScan Therapeutics
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell therapies for treating cancer patients. The company’s lead therapy candidates target hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation and aim to provide multiplex TCR-T therapies for various cancers through its ImmunoBank repository.
YTD Price Performance: -49.06%
Average Trading Volume: 314,861
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $158.5M
See more insights into TCRX stock on TipRanks’ Stock Analysis page.